Back

Prevention of atrial fibrillation with SGLT2 inhibitors across the spectrum of cardiovascular disorders: a meta-analysis of randomised controlled trials

30 August 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation Prevention ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Marcello Casuso Alvarez

S. Orsola-Malpighi Policlinic, Bologna (Italy)

6 More presentations in this session

Presentation thumbnail
Use of class ic antiarrhythmic drugs in atrial fibrillation with structural heart disease: a nationwide cohort study
Assistant Professor J. Jeong (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
A multicenter analysis of atrial fibrillation burden reduction with antiarrhythmic drugs in patients with cardiac implantable electronic devices
Doctor S. Schwartz (New York, US)
Abstract Slides Video
Presentation thumbnail
Improving management of patients with atrial fibrillation in the emergency department based on an aggressive rhythm control strategy. The HEROMEDICUS study.
Doctor N. Argyriou (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Impact of statin and ezetimibe for the prevention of stroke in patients with atrial fibrillation
Associate Professor K. Lee (Gwangju, KR)
Abstract Slides Video
Presentation thumbnail
The contemporary guideline-directed medical therapy (GDMT) for heart failure is associated with a reduced incidence of new-onset atrial fibrillation in the elderly patients
Doctor Y. Mukai (Fukuoka, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Antiarrhythmic and upstream pharmacological therapy in atrial fibrillation

The Event

Event poster

ESC Congress 2025

30 August 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved ejection fraction - A meta-analysis of randomised-controlled trials
thumbnail
Congress Presentation
Can SGLT2i use decrease the risk of atrial fibrillation in patients with heart failure with reduced ejection fraction: a retrospective cohort study
thumbnail
Congress Presentation
SGLT2i and AF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources